ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 152.3 USD | -1.32% |
|
+1.55% | -20.44% |
Presenter SpeechChristine Lindenboom (Executives)Welcome to Alnylam's R&D Day 2023. I'm Christ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
152.3
USD
Average target price
220.4
USD
Spread / Average Target
+44.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.44% | 19.26B | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B | |
| +18.74% | 11.58B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Transcript : Alnylam Pharmaceuticals, Inc. - Special Call